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Toshimitsu Hamasaki, MSC, PHD,yyyy Shinsuke Nanto, MD, PHD,zzzz on behalf of the OLIVE InvestigatorsABSTRACTOBJECTIVES This study sought to investigate the 3-year follow-up results of OLIVE registry patients.
BACKGROUND Although favorable 12-month clinical outcomesafter endovascular therapy (EVT) inOLIVE registry patients
with critical limb ischemia (CLI) from infrainguinal disease have been reported, long-term results after EVT remain unknown.
METHODS This was a prospective multicenter registry study that consecutively enrolled patients who received infrain-
guinal EVT for CLI. The primary outcomewas 3-year amputation-free survival (AFS), whereas secondary outcomemeasures
were 3-year freedom frommajor adverse limb events (MALE), wound-free survival, and wound recurrence rate. Prognostic
predictors for each outcome were also elucidated by Cox proportional hazard regression analysis or the log-rank test.
RESULTS The completion rate of 3-year follow-up was 95%. Three-year AFS, freedom from MALE, and wound-free
survival rates were 55.2%, 84.0%, and 49.6%, respectively. Wound recurrence out to 3 years was 43.9%. After
multivariable analysis, age (hazard ratio [HR]: 1.43, p ¼ 0.001), body mass index #18.5 (HR: 2.17, p ¼ 0.001), dialysis
(HR: 2.91, p < 0.001), and Rutherford 6 (HR: 1.64, p ¼ 0.047) were identiﬁed as predictors of 3-year major amputation or
death. Statin use (HR: 0.28, p ¼ 0.02), Rutherford 6 (HR: 2.40, p ¼ 0.02), straight-line ﬂow to the foot (HR: 0.27,
p ¼ 0.001), and heart failure (HR: 1.96, p ¼ 0.04) were identiﬁed as 3-year MALE predictors. Finally, CLI due to isolated
below-the-knee lesion was a wound recurrence predictor (HR: 4.28, p# 0.001). Three-year survival, freedom from major
amputation, and reintervention rates were 63.0%, 87.9%, and 43.2%.
CONCLUSIONS In CLI patients with infrainguinal lesions, 3-year clinical results of EVT were reasonable despite high
reintervention and moderate ulcer recurrence rate. (A Prospective, Multi-Center, Three-Year Follow-Up Study on
Endovascular Treatment for Infra-Inguinal Vessel in Patients With Critical Limb Ischemia [OLIVE 3-Year Follow-Up
Study]; UMIN000014759) (J Am Coll Cardiol Intv 2015;8:1493–502) © 2015 by the American College of Cardiology
Foundation.
ABBR EV I A T I ON S
AND ACRONYMS
AFS = amputation-free survival
BMI = body mass index
BTK = below-the-knee
BSX = bypass surgery
CI = conﬁdence interval
CLI = critical limb ischemia
EVT = endovascular treatment
HR = hazard ratio
MALE = major adverse limb
event(s)
PH = proportional hazard
From the *
sity, Ohash
Division, D
wada Toku
Cardiovasc
Fukuoka G
Cardiology
Kurume, J
{{Cardiova
Kobe, Japa
of Cardiolo
Matsuyam
kkkDepartm
Kasugai M
Medicine,
yyyyOfﬁce
zzzzNishino
Interventio
ration, Me
other auth
Manuscrip
Iida et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 1 , 2 0 1 5
3-Year Outcomes of the OLIVE Registry S E P T E M B E R 2 0 1 5 : 1 4 9 3 – 5 0 2
1494C urrently, endovascular treatment(EVT) has become commonplace asa treatment strategy for critical
limb ischemia (CLI) (1,2) because it achieves
comparable clinical outcomes to bypass sur-
gery (BSX), thanks to development of recent
catheter devices and because operative risk
is high in patients with severe CLI who also
present with concomitant morbidities such
as cardiovascular disease and heart failure
(3–7). However, prospective multicenter
studies especially focused on long-term out-
comes are limited in this particular ﬁeld.SEE PAGE 1503The BASIL (Bypass versus Angioplasty in Severe
Ischemia of the Leg) trial is the only prospective
multicenter study that evaluated long-term results
comparing EVT with BSX for CLI (8,9). However,
because the study population did not include dialysis
patients, and neither long balloons nor nitinol stents
were used, it did not reﬂect true clinical practice;
additionally, EVT device evaluation was not conduct-
ed (8,9). We subsequently demonstrated favorable
12-month results of EVT for CLI in the OLIVE (A Pro-
spective, Multi-Center, Three-Year Follow-Up Study
on Endovascular Treatment for Infra-Inguinal Vessel
in Patients With Critical Limb Ischemia) trial (the ﬁrst
prospective multicenter study by a wound core labo-
ratory) in a real-world setting (6). High intervention
and poor survival rates notwithstanding, reasonable
12-month results were obtained for freedom from ma-
jor amputation andwound healing. Herein, we present
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STUDY DESIGN. This was a prospective multicenter
registry study that consecutively enrolled patients
who underwent infrainguinal EVT for CLI. The
12-month results were reported previously (6), and
medium-term results out to 3 years were evaluated
in this study. Informed consent was obtained from
each subject before enrollment, and the study
protocol was approved by the ethics committee at
each participating institution. This study was
registered with UMIN-CTR (UMIN000014759; A
Prospective, Multi-Center, Three-Year Follow-Up
Study on Endovascular Treatment for Infra-
inguinal Vessel in Patients With Critical Limb
Ischemia).
STUDY PARTICIPANTS. A total of 314 subjects were
enrolled between December 2009 and July 2011 and
observed between December 2010 and July 2012.
The 3-year follow-up was completed in July 2014.
Inclusion and exclusion criteria have been described
previously (6). In brief, CLI patients without a his-
tory of major amputation whose lesions were
limited to the infrainguinal artery were included.
CLI patients with dementia, and those whose CLI
was due to acute arterial occlusion, nonarterial
sclerotic disease, or inﬂammatory disease were
excluded.
ENDOVASCULAR INTERVENTION. Details of the
endovascular procedure have also been described
previously (6). Brieﬂy, provisional stenting using
nitinol stents was conducted on femoral artery lesions,
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TABLE 1 Baseline Characteristics
Age, yrs 73.1  9.8 (312)
Age $80 yrs 82 (26)
Male 203 (65)
Body mass index, kg/m2 22.1  3.5 (304)
Body mass index <18.5, kg/m2 38 (13)
Serum albumin 3.7  0.5 (292)
Serum albumin <3.0 g/dl 19 (7)
Risk factors
Hypertension 248 (79)
Diabetes mellitus 223 (71)
HbA1c 6.2  1.2 (291)
Dyslipidemia 127 (41)
On statin treatment 81 (26)
History of smoking, past/current 123 (39)/37
(12)
Renal failure (serum creatinine
>1.5 mg/dl)
189 (61)
Hemodialysis 163 (52)
Anemia* 212 (68)
Hemoglobin <8.0 g/dl 4 (1.3)
CRP, median 0.7 [0.2–2.5] (294)
CRP >3.0 mg/dl 59 (20)
Cardiovascular disease
Prior coronary disease 143 (46)
Prior myocardial infarction 60 (19)
Prior cerebrovascular disease 66 (21)
Heart failure 80 (26)
Antiplatelet/anticoagulation
therapy
Aspirin 274 (88)
Clopidogrel 124 (40)
Cilostazol 160 (51)
Lower limb characteristics
Rutherford classiﬁcation
R4 38 (12)
R5 228 (73)
R6 46 (15)
Multiple ischemic wounds 62 (20)
Wound infection 48 (15)
ABI 0.70  0.22
(263)
ABI $0.9 51 (19)
ABI <0.4 16 (6)
SPP
Dorsal surface 26  12 (285)
Plantar surface 30  16 (282)
ADL before revascularization
Ambulatory 37 (12)
Wheelchair user 188 (63)
Bedridden 74 (25)
Values are mean  SD (n) or n (%). *Hemoglobin median <13 g/dl for men,
<11 g/dl for women.
ABI ¼ ankle brachial index; ADL ¼ activities of daily living; CRP ¼ C-reactive
protein; SPP ¼ skin perfusion pressure.
TABLE 2 Lesion Characteristics
Culprit lesion
FP þ BTK lesion 129 (41)
FP lesion 53 (17)
BTK lesion 130 (42)
FP lesions 182
TASC II classiﬁcation
Type A 39 (21)
Type B 37 (20)
Type C 43 (24)
Type D 63 (35)
BTK lesions 259
TASC 2000 classiﬁcation
Type C 11 (4)
Type D 248 (96)
Values are n (%).
BTK ¼ below the knee; FP ¼ femoropopliteal; TASC ¼ TransAtlantic Inter-
Society Consensus.
TABLE 3 Initial Results of EVT
Post-procedure
One straight-line ﬂow to foot 290 (93)
Post-procedure ABI 0.91  0.19 (230)
ABI $0.9 135 (59)
ABI <0.4 2 (0.9)
Post-procedure SPP
Dorsal surface—post-SPP 47  21 mm Hg (247)
Dorsal surface—change in SPP D21  22 mm Hg (235)
Plantar surface—post-SPP 45  20 mm Hg (250)
Plantar surface—change in SPP D15  21 mm Hg (233)
Values are mean  SD (n) or n (%).
ABI ¼ ankle brachial index; EVT ¼ endovascular therapy; SPP ¼ skin perfusion
pressure.
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1495on infrapopliteal lesions. During this study period,
drug-eluting stents and balloons for femoropopliteal
lesions and atherectomy devices for femorotibial
lesions were not available for peripheral intervention.WOUND CARE AND EVALUATION. Ischemic wounds
were assessed and managed by a plastic surgeon or
dermatologist. Wound management was carried out
regularly. Adjunctive therapies, including maggot
and hyperbaric therapy, were not performed, to
ensure standardized wound care. Wounds were pho-
tographed and evaluated independently out until
12 months as previously described (6), after which
they were followed and assessed according to the
protocol of each institution’s plastic surgery
department.
FOLLOW-UP. Follow-up was mandatory at 1, 3, 6, and
12 months. Thereafter, the follow-up protocol was
determined by each institution but was generally
conducted every 3 months. Reintervention was only
indicated for recurrence of rest pain or wounds or
for delayed wound healing. Patient survival, major
amputation, reintervention, and ulcer recurrence
FIGURE 1 Kaplan–Meier Survival Curve and Hazard Rate of
AFS Major Amputation or Death After EVT
(A) Kaplan–Meier survival curve demonstrating post-EVT ampu-
tation-free survival (AFS) of the index limb in 312 patients with
critical limb ischemia (CLI) due to infrainguinal lesions. AFS was
73.6%, 64.2%, and 55.2% at 12, 24, and 36 months, respec-
tively. (B) Hazard rate of AFS major amputation or death after
EVT. Vertical axis shows changes in hazard rate of major ampu-
tation or death followed up to 3 years, demonstrating that
the highest hazard rate of major amputation or death was
observed at 0 to 6 months. CI ¼ conﬁdence interval;
EVT ¼ endovascular treatment.
TABLE 4 Stepwise Analysis for Predictors of Amputation and
Death After EVT
HR
95% CI Wald
Lower Upper p Value
All
Age (per 10 yrs) 1.04 1.02 1.07 0.0003
BMI #18.5 kg/m2 2.21 1.35 3.61 0.002
Albumin >3.0 g/dl 0.83 0.40 1.75 0.62
Statin 0.81 0.49 1.34 0.41
Chronic dialysis 2.55 1.59 4.09 <0.0001
Anemia 1.28 0.81 2.03 0.30
CRP >3 mg/dl 0.98 0.58 1.65 0.92
Rutherford classiﬁcation
(N4 þ N5 vs. N6)
1.61 0.94 2.76 0.09
Infection 1.39 0.87 2.22 0.17
Ambulatory (wheel
chair þ bedridden)
1.94 0.83 4.52 0.13
History of cardiac
incompetence
1.26 0.81 1.96 0.30
Stepwise
Age (per 10 yrs) 1.43 1.15 1.78 0.001
BMI #18.5 kg/m2 2.17 1.36 3.45 0.001
Chronic dialysis 2.91 1.88 4.51 <0.0001
Rutherford classiﬁcation
(N4 þ N5 vs. N6)
1.64 1.01 2.65 0.047
Infection 1.51 0.97 2.34 0.07
Ambulatory (wheel
chair þ bedridden)
2.07 0.95 4.51 0.07
BMI ¼ body mass index; CI ¼ conﬁdence interval; HR ¼ hazard ratio; other
abbreviations as in Tables 1 and 3.
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were unable to visit the hospital.
ENDPOINTS. Primary outcome was 3-year amputation-
free survival (AFS). The following were evaluated:
1) difference in predictors for AFS in 1 and 3 years;
2) timing of inﬂuence of each factor; and 3) changes
in the hazard rate of major amputation or death.
Freedom from major adverse limb events (MALE)
and ulcer recurrence rates were evaluated as sec-
ondary outcome measures, and changes in the
hazard rate for MALE were analyzed. Predicting
factors for 3-year MALE were evaluated. Regardingwound assessment, wound-free survival at 1, 2, and
3 years, and post-recovery recurrence rates were
evaluated. Additionally, recurrence-predicting fac-
tors were assessed. Survival, freedom from major
amputation, and freedom from reintervention were
also analyzed.
DEFINITION OF OUTCOME PARAMETERS. AFS was
deﬁned as the absence of death or major amputation.
Major amputation was deﬁned as above-ankle
amputation. Either major amputation or major rein-
tervention was classiﬁed as a MALE. Reinterventions
consisted of both major and minor reinterventions.
Major reinterventions included bypass grafting,
jump grafting, and interposition graft revision, as
well as thrombectomy and thrombolysis for stents
with loss of patency. Minor reintervention was
deﬁned as percutaneous transluminal angioplasty
and/or stenting (10). Ulcer recurrence after more than
1 year included recurrences at the same site or at
different sites.
STATISTICAL ANALYSIS. Continuous variables were
expressed as the mean  SD, whereas categorical data
were expressed as numbers with percentages. Either
FIGURE 2 Kaplan–Meier Survival Curve and Hazard Rate of
MALE After EVT
(A) Kaplan–Meier survival curve demonstrating post-EVT
freedom from major adverse limb events (MALE) in 312 patients
with CLI due to infrainguinal lesions. Freedom from MALE was
88.3%, 86.4%, and 84.0% at 12, 24, and 36 months, respec-
tively. (B) Hazard rate of MALE after EVT. Vertical axis shows the
changes in hazard rate of MALE followed up to 3 years,
demonstrating that the highest hazard rate of MALE was
observed at 0 to 6 months. Abbreviations as in Figure 1.
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1497the proportional hazard (PH) regression analysis or
log-rank test was performed to examine variables
for associations with major amputation or death and
time to MALE. Logistic regression analysis or the
chi-square test was employed to examine variables
for associations with ulcer recurrence. The PH
assumption was investigated graphically using its
covariate-speciﬁc plot and also with a test based
on Schoenfeld’s residuals. Each variable showing
signiﬁcant association (p < 0.25) and additional
nonsigniﬁcant variables with potential clinical
importance were then introduced into the stepwise
multivariable PH regression model to identify
predictors of each time-to-event outcome. We set
p¼0.25 for entry into themodel and p¼0.05 to remain
in the model. We also investigated time-dependent
factors for major amputation or death and MALE that
could change during the observation period, and
incorporated them into the PHmodel. The hazard ratio
(HR) and its 95% conﬁdence interval (CI) were calcu-
lated for each possible risk factor. Furthermore,
Kaplan–Meier curves were drawn for AFS and time to
freedom from MALE. The rate of wound recurrence
out to 3 years after wound healing was analyzed by
univariable and multivariable stepwise logistic
regression analysis to identify risk factors on recur-
rence outcome. In the analysis of logistic or Cox
regression for AFS, MALE, and wound healing, the
between-center variance (in the ﬁnal model) could be
ignored enough to be small (p values were 0.22, 0.52,
and 0.98 in AFS, MALE, and wound healing, respec-
tively). The odds ratio and its 95% CI were calculated
for each possible risk factor. All statistical analyses
were performed with SAS version 9.3 for Windows
(SAS Institute, Cary, North Carolina).
RESULTS
PARTICIPATING PATIENTS. A total of 314 patients
were enrolled, with 312 evaluable patients remaining.
Ninety-ﬁve percent of patients were observed for the
entire 3-year period.
PATIENT/LOWER LIMB CHARACTERISTICS. Mean age
was 73  10 years, and 65% of the patients were male
(Table 1). Diabetes mellitus and hemodialysis were
observed in 71% and 52% of patients, respectively.
With respect to limb condition, tissue loss, and
wound infection were 88% (Rutherford 5: 73%,
Rutherford 6: 15%), and 15%, respectively.
UNDERLYING DISEASE AND INITIAL SUCCESS
RATES. Isolated below-the-knee (BTK) lesions were
culprit lesions in 42% of the patients, and a combi-
nation of femoropopliteal artery and BTK lesionswas observed in 41% of the patients (Tables 2 and 3).
Initial success, deﬁned as straight-line ﬂow to the
foot, was achieved in 93%, and the procedure
complication rate was 4.0% (12 of 304).
AFS AND FACTORS PREDICTING 1-YEAR AND
3-YEAR MAJOR AMPUTATION OR DEATH. Figure 1A
shows 3-year AFS. Three-year AFS rate was 55.2%.
Factors associated with 3-year major amputation or
death were age (HR: 1.43, 95% CI: 1.15 to 1.78,
p ¼ 0.001), body mass index (BMI) #18.5 (HR: 2.17,
95% CI: 1.36 to 3.45, p ¼ 0.001), chronic dialysis (HR:
2.91, 95% CI: 1.88 to 4.51, p < 0.001), and Rutherford
classiﬁcation 6 (HR: 1.64, 95% CI: 1.01 to 2.65,
p ¼ 0.047), as shown in Table 4. Previously reported
TABLE 5 Stepwise Analysis for Predictors of MALE After EVT
HR
95% CI Wald
Lower Upper p Value
All
Age (per 10 yrs) 0.98 0.95 1.01 0.27
BMI #18.5 kg/m2 3.13 0.74 14.3 0.12
Diabetes mellitus 1.41 0.61 3.26 0.42
Statin 0.28 0.10 0.81 0.02
Hemodialysis 1.32 0.61 2.86 0.48
CRP (per unit) 0.99 0.93 1.05 0.70
Rutherford classiﬁcation
(N4 þ N5 vs. N6)
2.21 0.95 5.17 0.07
Wound infection 1.29 0.56 2.99 0.55
One straight-line ﬂow to foot 0.20 0.08 0.52 0.001
History of cardiac
incompetence
1.86 0.95 3.62 0.07
Stepwise
Statin 0.28 0.10 0.78 0.02
Rutherford classiﬁcation
(N4 þ N5 vs. N6)
2.40 1.12 5.13 0.02
One straight-line ﬂow to foot 0.27 0.11 0.66 0.001
History of cardiac incompetence 1.96 1.02 3.77 0.04
MALE ¼ major adverse limb events; other abbreviations as in Tables 1, 3, and 4.
TABLE 6 Stepwise Analysis for Recurrence of Wound
OR
95% CI Wald
Lower Upper p Value
All
Male 1.61 0.74 3.52 0.23
Serum albumin <3.0 g/dl 2.72 0.42 17.61 0.29
Diabetes mellitus 1.75 0.76 4.01 0.19
Hemodialysis 1.52 0.74 3.14 0.26
Isolated below-the-knee lesions 4.54 2.20 9.37 <0.0001
Stepwise
Diabetes mellitus 2.05 0.94 4.45 0.07
Isolated below-the-knee lesions 4.28 2.15 8.53 <0.001
CI ¼ conﬁdence interval; OR ¼ odds ratio.
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1498factors associated with 1-year major amputation or
death were BMI #18.5 (HR: 2.22, 95% CI: 1.23 to 4.01,
p ¼ 0.0078), history of heart failure (HR: 1.73, 95% CI:
1.02 to 2.91, p ¼ 0.041), and wound infection (HR: 1.89,
95% CI: 1.07 to 3.32, p ¼ 0.0283). BMI was the only
factor common to both. Heart failure and wound
infection would affect only early outcomes, and
analysis was conducted by incorporating them as
covariates that affect AFS within 1 year, but not
thereafter. Wound infection was found not to be sig-
niﬁcant. When this was examined at 6 months instead
of 1 year, all factors became signiﬁcant. In other
words, heart failure and wound infection affected AFS
only within the ﬁrst 6 months. Figure 1B shows the
change in hazard rate of major amputation or death
followed out to 3 years, demonstrating that the high-
est hazard rate was observed at 0 to 6 months.
FREEDOM FROM MALE AND PREDICTING FACTORS
FOR 3-YEAR MALE. Three-year freedom from MALE
was 84.0% (Figure 2A). Table 5 shows factors associ-
ated with 3-year MALE: statin use (HR: 0.28, 95%
CI: 0.10 to 0.78, p ¼ 0.02), heart failure (HR: 1.96,
95% CI: 1.02 to 3.77, p ¼ 0.04), Rutherford classiﬁ-
cation 6 (HR: 2.40, 95% CI: 1.12 to 5.13, p ¼ 0.02), and
straight-line ﬂow to the foot (HR: 0.27, 95% CI: 0.11 to
0.66, p ¼ 0.001). Figure 2B shows change in hazard
rate of MALE followed out to 3 years, demonstrat-
ing that the highest hazard rate was observed at 0 to
6 months.
WOUND OUTCOME AND RECURRENCE PREDICTING
FACTORS. Rate of wound recurrence out to 3 years
was 43.9%. Multivariable analysis showed CLI due to
isolated BTK lesions as a predicting factor for wound
recurrence (Table 6). Wound-free survival rate is
shown in Figure 4. At 1, 2, and 3 years, wound-free
survival rates were, respectively, 58.9%, 54.8%, and
49.6% in the overall population; 55.9%, 50.6%, and
40.7% in patients with tissue loss; and 80.3%, 83.3%,
and 69.4% in patients with rest pain.
THREE-YEAR SURVIVAL, FREEDOM FROM MAJOR
AMPUTATION AND REINTERVENTION. Survival,
major amputation-free rates, and reintervention-free
rates are shown in Figure 3. At 3 years, overall sur-
vival rate was 63.0%, the major amputation-free rate
was 87.9%, and the freedom from reintervention rate
was 43.2%.
DISCUSSION
In our OLIVE 12-month follow-up paper (6), we
reported favorable EVT outcomes for CLI in real world
patients, 50% of whom were on hemodialysis. The
3-year outcome study further provided informationregarding long-term durability of EVT for CLI. In
addition, we found that the prognostic factors for AFS
seemed to change over time.
CHANGES OVER TIME IN FACTORS RELATED TO AFS.
Recent prospective trials have not systematically
studied the long-term durability of EVT. This study
demonstrated that AFS continued to decrease over
time after year 1 and reached 55.2% after year 3. This
is comparable with 3-year outcomes of previous trials,
although the present study included sicker patients
such as those on hemodialysis (Table 7). It is note-
worthy that factors predicting major amputation or
death changed over time. BMI was a predictor at both
FIGURE 3 Post-EVT Kaplan–Meier Survival Curves
(A) Kaplan–Meier survival curve demonstrating post-EVT overall survival in 312 patients with CLI due to infrainguinal lesions. Overall survival rate was 81.3%, 71.5%, and
63.0% at 12, 24, and 36 months, respectively. (B) Kaplan–Meier survival curve demonstrating post-EVT freedom from major amputation in 312 patients with CLI due to
infrainguinal lesions. Freedom from major amputation was 91.2%, 89.7%, and 87.9% at 12, 24, and 36 months, respectively. (C) Kaplan–Meier survival curve
demonstrating post-EVT freedom from any reintervention in 312 patients with CLI due to infrainguinal lesions. Freedom from any reintervention was 60.7%, 51.2%, and
43.2% at 12, 24, and 36 months, respectively. Abbreviations as in Figure 1.
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14991 year and 3 years, whereas heart failure and wound
infection only inﬂuenced AFS within 6 months after
EVT. That is, the short-term and long-term predictors
of AFS were different. Factors associated with ulcer
healing were short-term predictors for AFS, and pre-
sumably, were linked to survival. After ulcer healing,
these factors were no longer signiﬁcant, and other
factors related to long-term prognosis tended to
emerge. Six months also coincides with the period
when leg ulcers were healed in the OLIVE study,
suggesting that this might be an appropriate dura-
tion when evaluating the usefulness of new methods
of limb salvage. The previous notwithstanding,long-term observation is necessary to assess patient
survival.
FREEDOM FROM MALE. In this study, the MALE-free
rate was a favorable 84.0% after 3 years, whereas
AFS declined from 73.6% at 1 year to 55.2% after
3 years. Thus, the difference between AFS and the
MALE-free rates was 14.7% after 1 year and nearly
doubled to 28.8% by 3 years. This result is similar to
previous reports that patient survival is worse than
limb prognosis. A patent direct vascular connection
and Rutherford 6 classiﬁcation were signiﬁcant fac-
tors affecting 3-year freedom from MALE in this
FIGURE 4 Wound-Free Survival
(A) The wound-free survival in the overall population. The wound-free survival rate in the overall population was 58.9% at 1 year, 54.8% at 2 years, and 49.6% at
3 years. (B) The wound-free survival in patients with tissue loss. The wound-free survival rate in patients with tissue loss was 55.9% at 1 year, 50.6% at 2 years, and
40.7% at 3 years, respectively. (C) The wound-free survival in patients with the rest pain. The wound-free survival rate in patients with rest pain was 80.3% at 1 year,
83.3% at 2 years, and 69.4% at 3 years, respectively.
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1500study. Accordingly, short-term limb salvage appears
to positively inﬂuence long-term prognosis, which
may support the difference between vascular
patency and limb prognosis. In other words, post-
EVT wound healing leads to fewer amputations,
and these results are maintained at 3 years. Statin
therapy was a predictor of good long-term limb
prognosis. This ﬁnding agreed with the results of
recent studies demonstrating clinical beneﬁts of
statins for CLI patients (17,18).
ULCER RECURRENCE. CLI due to isolated BTK
lesions was identiﬁed as the only predicting factor for
ulcer recurrence. Restenosis after EVT for BTK lesions
was high, and the risk of wound recurrence is
commonly present, suggesting the signiﬁcance of foot
care and meticulous outpatient follow-up.
CLINICAL IMPLICATIONS. There is a paucity of
prospective multicenter studies especially focused
on long-term outcomes of EVT for CLI. The follow-up data for the OLIVE registry demonstrated that
the 3-year clinical results of EVT were reasonable
in CLI patients with infrainguinal lesions despite
high reintervention and moderate ulcer recurrence
rates; meanwhile, prognostic factors for clinical
endpoints seemed to change over time. Our
ﬁnding that prognostic factors differed over time
could be clinically useful in identifying the treat-
ment goals that change over time for CLI patients
with complex morbidity. Moreover, CLI due to
isolated BTK lesions was the only identiﬁed pre-
dicting factor for ulcer recurrence, suggesting the
signiﬁcance of foot care and meticulous outpatient
follow-up.
STUDY LIMITATIONS.
1. Study design: This was a single-arm study of EVT,
rather than a randomized controlled trial of EVT
versus BSX. However, this study evaluated 3-year
outcomes in patients who ﬁt the common clinical
TABLE 7 Recent Prospective Studies of CLI Patients With/Without Angioplasty
Study Name/
Treatment Modality
Multi/Single
Center Disease Stage
Number of Patients/
Frequency of
Patients With DM
Rest Pain/
Tissue Loss
(%)
Assess
Point Parameter %
Year of
Publication
First Author/
Study (Ref. #)
BASIL trial/bypass vs.
angioplasty
Multi Rest pain, ulcer 224/42% 25/75 (%) 1 yr AFS 71 2005 BASIL trial
participants (8)3 yr AFS 52
2 yr Mortality 12
Circulase trial/lipo-
ecraprost þ vs. placebo
(no angioplasty)
Multi Fontaine III–IV 177/53.7% 48/52 (%) 6 mo Major amputation 13.0 2006 Brass et al. (11)
6 mo Mortality 5.6
6 mo Amputation or death 17.5
PREVENT III/endovascular
vs. surgical vein
bypass graft
Multi Rest pain, ulcer 134/54% 5 mo MALE 30.2 2007 Berceli et al. (12)
AMS-INSIGHT/absorbable
metal stent vs.
angioplasty
Multi Rutherford 4–5 50/68.4% 28.1/71.9 (%) 1 mo Major amputation 3.5 2009 Bosiers et al. (13)
1 mo Mortality 1.8
6 mo Limb salvage 92.4
6 mo Survival 92.5
6 mo Primary patency 88.1
Angioplasty vs.
primary stenting
Single Rest pain,
ulcer (R4–6)
22/55% 4.5/95.5 (%) 1 yr Survival 69.3 2010 Randon et al. (14)
1 yr Limb salvage 90
1 yr Primary patency 66
DEBATE study/drug-eluting
balloons vs. angioplasty
Single Rest pain, ulcer
(R4–6), diabetes
67/100% 4.2/95.8 (%) 1 yr Mortality 4.5 2013 Liistro et al. (15)
1 yr Major amputation 1.5
IN.PACT DEEP trial/
drug-eluting balloons
vs. angioplasty
Multi Rest pain, ulcer
(R4–6)
119/68.9% 17.9/82.1 (%) 1 yr Composite of all-cause
death, major amputation,
and CD-TLR rates
25.2 2014 Zeller et al. (16)
1 yr Major amputation 3.6
1 yr AFS 89.2
1 yr Mortality 8.1
OLIVE registry/angioplasty
single arm
Multi Rutherford 4–6 312/71% 12/88 (%) 1 yr AFS 73.6 2013 Iida et al. (6)
3 yr AFS 55.2
1 yr MALE free 88.3
3 yr MALE free 84.0
1 yr Survival 81.3
3 yr Survival 63.0
AFS ¼ amputation-free survival; AMS-INSIGHT ¼ -absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis; BASIL ¼ Bypass versus Angioplasty in Severe
Ischaemia of the Leg; CD-TLR ¼ clinically driven target lesion revascularization; CLI ¼ critical limb ischemia; DEBATE ¼ Drug-eluting balloon in peripheral intervention for below the knee angioplasty
evaluation; DM ¼ diabetes mellitus; IN.PACT DEEP ¼ Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia; MALE ¼major adverse limb
events; OLIVE ¼ A Prospective, Multi-Center, Three-Year Follow-Up Study on Enfovascular Treatment for Infra-Inguinal Vessel in Patients, With Crtical limb Ischemia; PREVENT III ¼ a multicenter, ran-
domized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery.
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1501proﬁle (approximately 50% on maintenance dial-
ysis) in a prospective and multicenter manner.
2. Study population: This study included Japanese
patients only; therefore, resultsmay not necessarily
be extrapolated to apply to other populations.
3. Treatment strategy: The results of EVT were
not evaluated at a central lab. However, new
devices, including drug-eluting balloons, stents,
and atherectomy devices, were not approved in
Japan during the study period, so there was little
heterogeneity in treatment strategy.
4. Clinical assessment: Although ulcer recurrence
from year 1 onward was not evaluated by a central
lab, the standard wound treatment protocol was
used for all patients enrolled in this study, and the
outcomes of ulcer, patient, and vascular lesions
were conﬁrmed in 95% of the subjects.CONCLUSIONS
The 3-year clinical results of EVT were reasonable in
CLI patients with infrainguinal lesions despite a high
reintervention rate and moderate ulcer recurrence
rate. Prognostic factors for clinical endpoints changed
over time.
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PERSPECTIVES
WHAT IS KNOWN? Although EVT has become
commonplace as a treatment strategy for patients
with CLI, prospective studies, especially those focused on
long-term outcomes and dialysis patients, are limited.
WHAT IS NEW? This OLIVE registry demonstrated that
the 3-year clinical results of EVT were reasonable, despite
high reintervention and moderate ulcer recurrence rates.
Prognostic factors for clinical endpoints seemed to change
over time.
WHAT IS NEXT? It is essential that treatment goals
are identiﬁed and revised as necessary, in accordance
with the changing risk proﬁle of CLI patients. EVT ef-
ﬁcacy in these patients may be further improved by the
advent of new techniques and technologies. Finally, an
additional challenge may be establishing a treatment
strategy focused on improving CLI patient life
prognosis.
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